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First, I want to express my deep appreciation for the
honor of serving as president of our Society and for the
opportunity to share some thoughts with you today. For
the theme of my address, I propose to ask how genetic
advances will impact the practice of medicine over the
next decade or two—and what we, as members of the
American Society of Human Genetics, should be doing
to influence these developments. I will focus on dilemmas
that I perceive in prenatal genetics, on population-based
genotyping to bring significant changes to the practice
of adult medicine (considering both single-gene disorders
and more-complex traits), and on the potential to make
greater use of family-based genotyping for autosomal
dominant disorders. I will advocate using our genetic
knowledge to advance the practice of medicine, and I
will take the liberty of being a bit provocative and spec-
ulative. Some of you may disagree with certain of my
perspectives, but healthy disagreement may stimulate
new intellectual contributions and dialogue and might
even provoke us to develop new technologies that will
move our discipline forward.
I would like to begin with a bit of historical perspec-
tive. In 1931, after 3 decades of seminal observations,
Sir Archibald Garrod wrote that “diathesis is nothing
else but chemical individuality,” which he explained in
remarkably prescient molecular and chromosomal terms
as follows: “[T]he factors which confer upon us our
predispositions to and immunities from the various mis-
haps which are spoken of as diseases, are inherent in
our very chemical structure, and even in the molecular
groupings which confer upon us our individualities, and
which went to the making of the chromosomes from
which we sprang” (Garrod 1931).
In more recent years, many of our colleagues have
emphasized the theme of genetic individuality and its
relevance to the practice of medicine. For instance, many
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of you will remember Charles Scriver’s elegant lectures
since the 1970s, which conveyed the potential for using
genetic screening for disease intervention in the adult
population, through the image of the artist Folon de-
picting “the man in the red hat” in a crowd (Scriver
1979). Are we ready to translate Garrod’s concept of
chemical individuality as depicted by the man in the red
hat into a genotype-based practice of medicine?
It is instructive to look back at some of the major
advances of the last 25 or more years that are related
to our field. The advent of testing and treatment for
phenylketonuria (PKU) epitomizes what we would hope
to achieve again and again throughout the practice of
adult as well as pediatric medicine. Improved methods
of chromosome analysis, including banded karyotypes
and FISH, have greatly advanced our diagnostic capac-
ity. Prenatal diagnosis, particularly for cytogenetic ab-
normalities, and maternal serum–screening programs
have become mainstays of obstetrical care. Population-
based heterozygote testing for conditions such as Tay-
Sachs disease and b-thalassemia has dramatically re-
duced the prevalence of these conditions in many parts
of the world. The use of folic acid for prevention of
neural-tube defects is an important therapeutic advance.
Genetic diagnosis and risk counseling have become sub-
stantial medical disciplines in their own right. Other ad-
vances have included cloning disease genes and mutation
detection for almost all the common single-gene disor-
ders, delineation of novel genetic concepts such as ex-
panding triplet repeats, and many more developments
that have made the recent meetings of our Society so
extraordinarily stimulating. The already substantial out-
put of the Human Genome Project is changing our dis-
cipline. Protein-replacement therapies for hemophilias,
adenosine deaminase deficiency, and Gaucher disease are
significant therapeutic advances, and exciting new data
for iduronidase were presented this morning. Although
only indirectly related to human genetic research, the
development of 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors deserves mention
because of their impressive potential for preventing cor-
onary atherosclerosis, an extremely common genetically
influenced disease. Finally, I would mention forensic
DNA testing as a direct outgrowth of research in our
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discipline that yields many benefits to society, such as
more-accurate identification of criminals and protection
of the falsely accused. Each of us could add to this list,
but it is important to note that there have also been
major disappointments, particularly the lack of effective
therapies for the many disorders that we can diagnose
so precisely.
Leaving the past and turning to the present and future,
I will begin with dilemmas that we face in reproductive
and prenatal genetics. I would describe certain disorders
that appear most challenging as “seemingly insurmount-
able”—insurmountable in the sense that I find it difficult
to envision curative therapeutic advances. In this group
I include disorders that are difficult or impossible to
anticipate prior to conception and that are accompanied
by a developmental injury likely to be irreversible by the
time of birth. This group includes the majority of cy-
togenetic disorders, such as trisomies and de novo de-
letion syndromes. For example, my laboratory has con-
tributed to the identification of the gene for Angelman
syndrome, but it troubles me that this discovery is un-
likely to have much immediate effect on the prevalence
of or disability associated with the condition. Also seem-
ingly insurmountable are hundreds of rarer recessive dis-
orders for which population-based heterozygote testing
may not be feasible (e.g., Meckel syndrome) and de novo
dominant mutations (e.g., thanatophoric dysplasia and
osteogenesis imperfecta type II). Ask yourself how many
of the elegant mutation studies of malformation disor-
ders that you are hearing described at this meeting will
dramatically impact the prevalence or burden of the dis-
order anytime soon. This group of cytogenetic and sin-
gle-gene disorders includes a wide spectrum with some
severe and some milder phenotypes. Some of the con-
ditions may be amenable eventually to prenatal or post-
natal treatment of varying effectiveness. But, returning
to our meeting 20 years hence, we may well find that
definitive intervention for the cytogenetic and single-
gene developmental disorders that we know today is
little changed.
Looking forward, I feel assured that diagnostic ad-
vances with newer cytogenetic technologies will allow
for the identification of novel disorders, particularly ter-
minal deletions, smaller interstitial deletions and dupli-
cations, and more-subtle rearrangements. In addition, it
is at least possible that sampling fetal cells in the ma-
ternal circulation could dramatically alter the prenatal-
diagnosis landscape. Some of our most persistent chal-
lenges, however, are dilemmas of reproductive avoid-
ance. The first two dilemmas confront individual fam-
ilies and societies as a whole. They are not dilemmas of
genetics or current technology but ones of ethics, social
mores, and religious beliefs. Once aware of genetic risks,
couples must first decide whether they wish to use pre-
natal testing, in the form of either carrier testing or fetal
testing. If fetal test results snatch the hope for a normal,
healthy child from the family, they then face the second
dilemma of two grim options: termination of the preg-
nancy or birth of a disabled infant.
There is another dilemma that I see for us as geneti-
cists. Should we continue current approaches, or should
prenatal diagnosis be offered to all families as an option
for those seeking maximal screening? Prenatal diagnosis
could be expanded not only by offering testing to all
families but also by testing for a much wider group of
disorders. The technology is in place—and much of the
methodology has been in place for many years—to ac-
complish prenatal diagnosis for virtually all cytogenetic
disorders and numerous other single-gene abnormalities.
I believe that we—society at large and the medical prac-
titioners—would make use of prenatal diagnosis for vir-
tually all pregnancies and test for a very wide range of
disorders, if curative therapies were available but effec-
tive only if implemented during the second trimester.
Why do we choose not to offer the option of prenatal
diagnosis for all pregnancies? I do not accept that this
is a matter of cost or even a matter of maternal and fetal
risk, given current technology. The willingness to invest
huge sums in treatments that offer the hope or the cer-
tainty of major benefits, such as bone-marrow trans-
plantation for advanced cancer or enzyme replacement
for Gaucher disease, demonstrates that, at least in the
United States (and probably in many other Western so-
cieties), there would be a readiness to bear the costs of
universal prenatal diagnosis, if cures for the disorders in
question were available. Rather, I believe it is societal
ambivalence and differences of opinion regarding abor-
tion, as the only alternative for avoidance of many dis-
orders, that restrain the use of prenatal diagnosis.
Interestingly, there are intense efforts to enhance mater-
nal-serum screening, and this emphasis has considerable
merit but seems ambivalent—ambivalent in the sense
that we would not emphasize a strategy that detects only
a fraction of cases but, rather, would insist on a plan to
detect 100% of cases if a cure were available. If prenatal
detection were focused on curative intervention rather
than selective abortion, I suspect that the emphasis
would be on universal prenatal sampling and on auto-
mation and high-throughput methods to detect as many
disorders as possible
In expanded reproductive screening, it is certainly fea-
sible to envision much broader programs for identifying
affected fetuses or couples at risk. Population-based car-
rier testing for cystic fibrosis (CF) is one example, but
intense debate has surrounded this option. I have long
advocated more widespread offering of CF-carrier test-
ing, and I emphasize “offering” in a very nondirective
fashion. More recently, the recommendations are in-
creasingly toward offering testing. If we imagine various
high-throughput technologies, we could consider testing
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for Duchenne muscular dystrophy, fragile X syndrome,
perhaps spinal muscular atrophy, cytogenetic microde-
letions, and various ethnic-specific risks. There are often
choices between carrier screening for parents and testing
fetuses. Each has disease-specific advantages and dis-
advantages. Preconception testing of parents for reces-
sive carrier status or women for Duchenne muscular dys-
trophy or fragile X syndrome offers a broader range of
reproductive options. However, fetal testing is the only
option for most microdeletions, offers advantages in
testing males for X-linked disorders, and can be consid-
ered for recessive disorders in various screening strate-
gies. We already see reports of pilot programs screening
for fragile X syndrome and other disorders, and ex-
panded ethnic mutation testing is common in the Ash-
kenazic population. There can be substantial difficulties,
such as the prediction of the phenotypic effect in the
case of female fetuses with fragile X, but more wide-
spread testing is being evaluated and may become more
or less attractive, depending on factors such as prenatal
or postnatal therapeutic advances.
So, what actions might be appropriate under the cir-
cumstances? First, there is the possibility that some
young inventive mind in this audience might be able to
develop a strategy to solve these dilemmas for many
disorders, by reducing the frequency of nondisjunction
or preventing the conception or implantation of affected
embryos. A miraculous way to suppress nondisjunction
or cure cytogenetically abnormal fetuses would be far
preferable to selective termination of pregnancy, but
such advances currently seem out of reach. Universal
preimplantation diagnosis would be a theoretical but
ridiculously impractical option. Second, we should not
abandon efforts to develop postnatal treatments, even if
such may be only palliative and feasible for only a few
disorders. Third, I believe it is worthwhile to acknowl-
edge the seemingly insurmountable factor, confront these
dilemmas, promote societal understanding of the prob-
lems, and avoid offering false hope that all genetic dis-
ease is necessarily treatable in the foreseeable future.
Finally, we should consider and debate offering ex-
panded preconception carrier testing and prenatal di-
agnosis for all pregnancies to those families that desire
maximal screening. If ambivalence about selective ter-
mination of pregnancy is a pivotal variable, as I suggest,
then logic might dictate offering expanded services to
families seeking maximal prenatal assessment—and re-
maining nondirective toward and supportive of families,
whether they decline or seek such services. I would sug-
gest that we vigorously investigate the societal, tech-
nological, and economic aspects of offering universal
expanded strategies for reproductive avoidance to fam-
ilies seeking such services. Of all the challenges that I
will discuss, I believe that finding better solutions to
these dilemmas of reproductive avoidance is the most
difficult. So I conclude with a paradoxical message: We
desperately need better options than selective termina-
tion of pregnancy, but, until we have them, maybe we
should make the only options we have more widely
available.
Now, I will leave reproductive questions and take up
what I have termed “genomic medicine” in the title of
my presentation, “Making Genomic Medicine a Real-
ity.” I would define genomic medicine as the routine use
of genotypic analysis, usually in the form of DNA test-
ing, to enhance the quality of medical care. On the one
hand, we can envision a revolution of individualized,
genotype-based medicine harking back to the insights of
Garrod (1931) and the urgings of Charles Scriver (1979).
On the other hand, genomic medicine might prove a
disappointment and remain confined to a minor role. In
addition, there are very appropriate and substantial
fears of predictive testing in the absence of definitive
intervention.
I am going to assume that certain advances are as-
sured. The Human Genome Project will be completed
in the near future, and this will identify all human genes.
We had a report just this week that perhaps half of all
human genes are now identified (GeneMap ’98; also see
Deloukas et al. 1998). I think we can also assume that
disease-related mutations and polymorphisms will con-
tinue to be identified at a rapid pace. It is also likely that
we will have new technology, such as DNA chips (South-
ern 1996), that will allow for the economical collection
of nearly unlimited amounts of genotypic information
on a routine basis.
The widespread use of genotyping in the practice of
medicine would not involve new principles. Newborn
screening for PKU is a model that we can and should
carry to the adult population. We have evolved principles
for determining which newborn-screening tests are ap-
propriate, depending primarily on the availability of
therapeutic intervention, and this requirement for effec-
tive intervention should be applied to adult screening.
We also see numerous examples in adult medicine that
provide precedent for population-based screening to
achieve therapeutic benefits. These include testing for
hypertension, glaucoma, and cholesterol, as well as rou-
tine mammography and measurement of prostate-spe-
cific antigen. While some might argue that certain forms
of screening are for disease rather than predisposition,
the distinction between predisposition and disease is of-
ten not as clear as might be imagined. Is hypertension
a disease or predisposition to a stroke? Is hypercholes-
terolemia a disease or predisposition to myocardial in-
farction? Is a germ-line mutation for hereditary non-
polyposis colon cancer (HNPCC) a predisposition to
disease or an early stage of colon cancer? Although most
of us would answer that an HNPCC mutation is a pre-
disposition, the distinction is not always clear. Some
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forms of well-accepted screening in the adult popula-
tion—such as screening for cholesterol, hypertension,
and glaucoma—are analogous to many potential forms
of genotypic screening.
In the context of population-based genotyping, the
difference between ancient mutations and recent muta-
tions is relevant. Ancient mutations can confer the same
genetic risks on thousands or millions of individuals in
the population, while recent mutations will affect one
or a few individuals. Obvious examples of ancient mu-
tations include the sickle cell–anemia mutation, the a1-
antitrypsin Z allele, apolipoprotein E (apo E) polymor-
phisms, factor V Leiden, some BRCA1 mutations, pre-
mutations for triplet repeats, and innumerable recessive
alleles. It is easier to screen for ancient mutations, since
we can search for specific known alleles. There typically
are substantial differences in the frequency of ancient
mutations in different ethnic groups. The circumstances
are somewhat different for recent mutations, which are
often found with deleterious dominant or X-linked con-
ditions that have an impact on reproductive fitness. Ex-
amples would include Duchenne muscular dystrophy,
Marfan syndrome, and neurofibromatosis. Laboratory
testing is more difficult because of the different mutation
in each family, although it is increasingly possible, with
newer technologies, to screen genes for any mutation,
on a routine basis. Typically, there are minimal differ-
ences between ethnic groups, in the frequency of these
more recent and short-lived mutations. There are dis-
orders in which a combination of ancient and recent
mutations contributes to the incidence, with both par-
ticular alleles in specific ethnic populations and still ex-
tensive heterogeneity among families, as exemplified by
BRCA1 and BRCA2. Of course, there is also the fasci-
nating example of achondroplasia, in which de novo
mutations are extremely common but the same mutation
recurs. The potential value of population-based geno-
typing in the practice of medicine will be influenced by
the extent to which ancient mutations contribute to risk
factors for common adult diseases. The greater the role
of ancient mutations, the greater the potential to screen
for at-risk genotypes and develop specific interventions.
Using newborn screening as a model, we should attempt
to identify instances where population-based genotyping
will enhance the practice of adult medicine and bring
significant benefits to the population.
One potential application of genomic medicine relates
to “pharmacogenomics,” a term that is used loosely to
describe a number of different concepts and strategies.
First, we are all familiar with traditional pharmacoge-
netics, or those genotypic variations that alter responses
to drugs. G6PD deficiency, malignant hyperthermia, bu-
tyrylcholinesterase deficiency, and the debrisoquine hy-
droxylase polymorphism are examples (Daly 1995).
Universal genotyping for a much-expanded panel of
pharmacogenetic traits could significantly improve the
risk-benefit ratio for many medications, and we might
strive to realize this attractive promise over the coming
decade. There is evidence for genotypic susceptibility to
aminoglycoside-induced deafness (Fischel-Ghodsian et
al. 1997) and to death from 6-mercaptopurine admin-
istration (Daly 1995); genotyping could reduce or elim-
inate these risks. An extension of pharmacogenetics is
the potential to resurrect drugs abandoned because of
side effects or to improve the possibilities, through ex-
tensive pharmacogenetic testing, for new drugs depen-
dent on the avoidance of untoward reactions. A further
variation on the pharmacogenomic theme is to use ex-
tensive genotyping, perhaps including a large group of
single-nucleotide polymorphisms (SNPs), to identify re-
sponder subgroups. Yet another application is the de-
velopment of novel pharmaceuticals for specific geno-
types, based on new insights derived from a genetic
dissection of pathogenesis. We already have diverse ther-
apies—hematin for porphyria, hormone replacement for
congenital adrenal hyperplasia, phenylacetate for sickle-
cell anemia, and factor replacement for hemophilia—in
which some level of understanding of pathogenesis al-
lows the development of a specific intervention. There
might be good reason to believe that specific therapeutics
may one day be developed for triplet-repeat neurode-
generative disorders or other single-gene conditions, but
even more important is the possibility that genotype-
specific therapeutics will be applicable to more-common
disorders such as asthma, schizophrenia, or hyperten-
sion. Perhaps an understanding of the role of the pre-
senilins or apo E in the pathogenesis of Alzheimer disease
will lead to the development of novel drugs that could
prevent development of disease without regard to ge-
notype. Finally, the pharmaceutical industry sometimes
uses the term “pharmacogenomics” to refer to the strat-
egy of using information from the Human Genome Pro-
ject to identify new drug targets.
In conclusion, there is a broad range of pharmaco-
genomic concepts and strategies, many of which might
justify universal genotyping to provide higher-quality
medical care. As we consider the possibility of popula-
tion-based DNA testing for pharmacogenetic traits, the
benefits are attractive, since effective intervention is often
simply avoidance of offending drugs. The risk of dis-
crimination is minimal, and the disadvantages are pri-
marily the costs of such a program and the modest num-
ber of individuals benefiting, but these disadvantages
might be ameliorated by efficiencies of multiplex testing.
Turning from pharmacogenomic perspectives to spe-
cific diseases, we might ask, further, whether DNA
screening for the adult population as part of routine
primary care will be justified soon—and whether there
are genotypes and disorders that are attractive candi-
dates at present. I will comment briefly on a1-antitrypsin
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deficiency, hemochromatosis, factor V Leiden, and apo
E in this context. The a1-antitrypsin ZZ genotype con-
fers a high risk of emphysema and has a frequency of
∼1/5,000 in the U.S. Caucasian population, with a
higher incidence in some European populations (Cox
1995). Smoking is a crucial variable in survival, and
counseling for smoking cessation or avoidance is a po-
tentially important intervention. Recombinant-protein
therapy is under evaluation, and gene therapy is a pos-
sibility for the future. Do the potential benefits justify
population-based testing? There is a dramatic reduction
in morbidity and mortality if smoking is avoided. The
age for 50% survival is ∼40 years for ZZ smokers, com-
pared with 160 years for ZZ nonsmokers (Larsson
1978). One could argue either that the current absence
of population-based screening for a1-antitrypsin is a
missed opportunity for genomic medicine or that the
current lack of screening provides evidence that genomic
medicine will not be embraced by the medical establish-
ment. Alternatively, perhaps the current intervention is
not adequate, so that the case for ZZ screening is not
compelling. The answer likely hinges on the effectiveness
of intervention, a recurring theme in evaluating the po-
tential for genomic medicine. If further research indi-
cated that 90% of ZZ individuals would avoid smoking
if they knew their genotype and risks early in life, or if
a pharmacological or gene-therapy cure were available,
the justification for screening programs would become
compelling. Perhaps it is unrealistic to hope for dramatic
behavior modification, although a Swedish study found
that only 10% of 18-year-olds detected as ZZ through
newborn screening smoked, compared with 21% of con-
trols (Sveger et al. 1995).
I would like to turn to hemochromatosis, which I have
long seen as an extraordinary opportunity for popula-
tion-based screening to save lives. Even before cloning
the gene, we could anticipate the existence of a few com-
mon mutations based on linkage-disequilibrium data,
and an effective treatment was well established. He-
mochromatosis is an autosomal recessive disorder that
causes life-threatening damage to the liver, heart, pan-
creas, and other organs (Bothwell et al. 1995). The fre-
quency of homozygotes for susceptibility is remarkably
high, with 1/200–500 Caucasians at risk. Men are more
often symptomatic in approximately a 5:1 ratio, and
alcohol intake is a risk factor. The treatment is avoidance
of iron supplements and removal of blood—and, thus,
iron—by phlebotomy, if iron overload develops. The
available data suggest that outcome is excellent if treat-
ment is implemented early. The penetrance for a ho-
mozygous susceptibility genotype in hemochromatosis is
uncertain, but a much higher frequency is found when
populations are screened for serum iron elevations than
when symptomatic probands are diagnosed. The gene
for hemochromatosis, designated “HFE,” was cloned in
1996 (Feder et al. 1996). Two mutations, C282Y and
H63D, are particularly common, and various DNA stud-
ies have found two mutant alleles in 70%–95%—or
even 100%—of symptomatic probands (Burke et al.
1998). Thus, there is the potential to dramatically reduce
or eliminate morbidity and mortality from hemochro-
matosis, through population-based genotyping. Individ-
uals with at-risk genotypes could be monitored, and
phlebotomy initiated, if iron overload occurs.
A consensus conference convened March 3, 1997, by
the Centers for Disease Control and Prevention and the
National Human Genome Research Institute specifically
addressed the question of population-based screening by
DNA analysis (Burke et al. 1998). A prestigious group
recommended against population-based screening for
hemochromatosis at this time and identified concerns
regarding prevalence, penetrance, optimal care, stig-
matization, and discrimination. It was recommended
that there be a high priority for population-based re-
search. Despite this recommendation, I believe there is
still room for considerable concern regarding the proper
course of action. Even prior to cloning of the gene, pop-
ulation screening by serum iron was recommended by
the College of American Pathologists (Witte et al. 1996).
I am troubled by the consensus recommendation against
screening, and I believe there may be considerably
greater benefits to proceeding with screening rather than
delaying, recognizing the uncertainties. On the basis of
reports of the incidence of symptomatic probands (Both-
well et al. 1995; Burke et al. 1998), there is the potential
to save 250–1,000 lives/year in the United States, or
more, if underdiagnosis of symptomatic individuals is
significant; these numbers compare to ∼200 new phen-
ylketonurics diagnosed per year. The situation is remi-
niscent of the early days of PKU treatment. If we had
delayed dietary therapy for PKU until we had all the
answers, many more children would have suffered ir-
reversible brain damage. I fail to see a significant threat
of stigmatization or discrimination for a disorder for
which there is agreement that effective treatment is avail-
able. We are the most informed consumers in this area,
and I suspect that most of us would decline apo E testing
for Alzheimer disease (which I will discuss in a moment)
but would welcome hemochromatosis testing. If it would
be good for us, why not for the rest of the population?
Would a patient diagnosed in the terminal untreatable
phase of this disease 2–3 years hence have a legitimate
retrospective complaint that screening was not per-
formed in earlier years? Screening for hemochromatosis
may be primarily a question of how rapidly to proceed,
rather than deep disagreement, but I believe that pop-
ulation-based screening will become routine soon, per-
haps due more to changes in perception than to new
data.
If we consider factor V Leiden, we learn that this
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Figure 1 Two types of complexity within complex traits
mutation causes resistance of factor V to degradation
by activated protein C. Heterozygosity for the mutation
is remarkably frequent, with 6% of the population being
a representative number. One study found a 2.7-fold
relative risk for venous thrombosis overall and as high
as a 7-fold increased risk for primary disease in older
men (Ridker et al. 1995). What remains to be determined
is whether there is an effective intervention that should
be offered on a routine basis to individuals with this
genotype. Another interesting question might be whether
the genotype represents a risk factor for thrombosis with
birth control pills, in which case screening prior to ad-
ministration would be relevant. It is reasonable to imag-
ine that existing or novel drug therapies might be in-
dicated on a prophylactic basis for individuals with
factor V Leiden, under at least certain circumstances.
Factor V Leiden represents a very interesting example
where the uncertain benefits relative to burdens, such as
undue anxiety, make it difficult to argue for routine ge-
notyping at present, although this could change. Factor
V Leiden exemplifies the many complexities that we will
face in determining whether genotypes of modest effect
or penetrance are suitable for screening.
Apo E genotyping poses a thought-provoking situa-
tion. The 2/2 genotype is associated with type III hy-
perlipoproteinemia. Heterozygosity for the 4 allele is as-
sociated with increased risk and/or earlier onset of
Alzheimer disease. Importantly, 35%–50% of Alzheimer
patients do not have the 4 allele. The risk is higher for
Alzheimer disease in 4/4 homozygotes. There is certainly
general agreement at present that genotyping for apo E
is not appropriate as a presymptomatic assessment for
risk of Alzheimer disease (ACMG/ASHG Working
Group on ApoE and Alzheimer Testing 1995). However,
if novel pharmacotherapies or other interventions were
developed that reduced, delayed, or eliminated this risk,
a case might evolve in favor of population-based ge-
notyping. On the other hand, one might imagine new
interventions that were relevant to the occurrence of Alz-
heimer disease generally raising questions of population-
based therapeutics without regard to genotype, perhaps
more reminiscent of the use of folate supplementation
for prevention of neural-tube defects.
Although everyone may not be convinced quite yet,
it is likely that primary-care medicine will soon incor-
porate age-related panels for genetic screening focused
on those disorders for which there is compelling ther-
apeutic intervention. We might envision a young-adult
screening panel—and perhaps a childhood or adolescent
panel—for those disorders where earlier intervention
was shown to be essential. These panels would probably
evolve rather rapidly over the next 2 decades, and testing
might be repeated at intervals, because the panel used
in 2005 will be quite outmoded compared with that
available in 2010. The single most important variable
in pursuing this strategy is the need for effective inter-
vention for those individuals identified as having specific
genotypes. This requirement substantially reduces con-
cerns that individuals will suffer discrimination or undue
anxiety based on genotype. When intervention is ben-
eficial but not completely effective, it will be more dif-
ficult to balance the risks and benefits of screening. It is
likely and appropriate that societies will incorporate le-
gal prohibitions against discrimination based on geno-
type, which would help in maximizing the benefit and
minimizing the risk of these strategies. There may be an
important threshold effect for population-based DNA
testing. Perhaps this strategy awaits a single compelling
application to justify implementation, as was the case
for PKU and newborn screening; hemochromatosis may
prove to be the icebreaker for population-based screen-
ing in adults. If this were to occur, the cost of adding
tests would be significantly reduced as the processes for
consent, sample collection, and reporting could serve for
multiple tests. Multiplexing disease-specific genotyping
with pharmacogenetic testing might be an attractive
early option. The understanding and consent for such
strategies could become as routine as those for meas-
uring blood pressure or cholesterol in today’s medical
care. We can anticipate great challenges in the education
of medical providers and the public, but the education
process is likely to parallel rather than precede imple-
mentation. Perhaps the education experiences will be
similar to that for maternal-serum screening, with a gen-
erous mix of deficiencies and successes but eventual
achievement of understanding comparable to that for
any other aspect of complex modern medicine. Any
screening panel for reproductive risks unrelated to the
health of the individual should presumably be main-
tained as a separate process, with the informed-consent
requirements for reproductive screening being substan-
tially different from those for general health screening.
Next I will consider how complex traits might fit into
this futuristic genomic medicine. Let me begin by dis-
tinguishing two types of complexity with relevance to
genotype-based diagnosis and treatment (fig. 1). One
instance involves phenotypes in which multiple loci con-
tribute to increased genetic susceptibility in individual
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Figure 2 A continuum of genetic complexity. This continuum
can be considered among disorders ranging from single gene, to major
gene, to complex trait but can also be considered in the context of
individual subjects within a single phenotype such as Hirschsprung
disease, hypertension, or coronary atherosclerosis.
patients, what I might call “truly complex traits.” Type
1 diabetes mellitus and most cases of coronary athero-
sclerosis are likely to fit such a model. This can be con-
trasted with complexity involving multiple single-gene
disorders giving rise to a single phenotype, essentially
representing examples of locus heterogeneity. In the lat-
ter case, a single major locus is the determining factor
in any one patient or family. Research on complex traits
often will not be able to distinguish prospectively those
instances where multiple loci contribute to disease in a
single individual from instances of phenotypically sim-
ilar single-gene disorders. The distinction may be only
a retrospective one, and both types of complexity will
often exist within a single disorder. It is worthwhile to
emphasize the perspective that there is no boundary be-
tween single-gene disorders and complex traits. Virtually
all single-gene disorders are subject to modifier effects
by the remainder of the genotype. This is particularly
true for dominant mutations and genotypes with low
penetrance. Figure 2 depicts this continuum, including
a single-gene example with small modifier effects, a case
determined by a major-gene effect with more substantial
modifiers, and a more complex trait with many genes
contributing modest effects. Nongenetic factors mod-
ify—or, here, rain down onall of these underlying ge-
notypes. In many cases, this should be thought of as a
continuum of individual subjects within a single disor-
der—with a proportion of cases having single-gene, ma-
jor-gene, or complex genetic effects—rather than as a
continuum of different disorders. We can imagine vir-
tually any number of genes contributing to a phenotype,
with the impact of any one locus ranging from minimal
to major, so that there are virtually infinite combinatorial
possibilities for genetic contribution to susceptibility to
any disease process.
If we ask about recent dramatic progress in the eti-
ology of complex traits, our attention is likely to be
drawn to maturity-onset diabetes of the young (MODY),
Hirschsprung disease, and some single-gene forms of hy-
pertension. Heterozygous mutations at any of at least
four loci are now known to cause MODY, including
glucokinase and three different hepatocyte nuclear-tran-
scription factors (Vionnet et al. 1992; Yamagata et al.
1996a, 1996b; Horikawa et al. 1997). In the case of
Hirschsprung disease, heterozygous mutations have been
identified for at least five or six genes, including theRET
oncogene and those for glial-cell line–derived neuro-
trophic-factor receptor (GDNF)–a, Sox 10, endothelin-
B receptor, endothelin 3, and neurturin (Attie et al. 1995;
Edery et al. 1996; Hofstra et al. 1997; Doray et al. 1998;
Kuhlbrodt et al. 1998; Tanaka et al. 1998). The RET
oncogene is the major player. Although the genetics of
Hirschsprung disease is somewhat complex, with
modifier effects and possible digenic inheritance,
MODY—and, to some extent, Hirschsprung dis-
ease—seem to me to be complex primarily in the same
way that Sanfilippo diseases A–D, with four different
enzyme defects, are complex—that is, they represent ex-
amples of locus heterogeneity for single-gene disorders.
These examples alert us to the possibility that hetero-
geneity of single-gene or major-gene effects may be more
extensive within complex traits than we anticipate—or,
at least, that progress in dissecting genetic factors may
come more readily in such cases.
Similarly, there are now numerous single-gene disor-
ders identified as causing hypertension, including glu-
cocorticoid-remediable aldosteronism caused by une-
qual crossing-over affecting the aldosterone synthase
locus; apparent mineralocorticoid excess caused by mu-
tations of 11 b-hydroxysteroid dehydrogenase; and
pseudohyperaldosteronism caused by activating muta-
tions in either of two subunits for a renal sodium channel
(Lifton 1996). The case of unequal crossing-over putting
the aldosterone synthase–coding region under control of
the ACTH-inducible 11b-hydroxylase promoter is par-
ticularly satisfying, since a genotype-specific therapy
based on corticosteroid administration is highly bene-
ficial. Perhaps the sodium-channel loci are intriguing as
candidates for harboring milder polymorphic alleles that
could predispose to more-common forms of hyperten-
sion. Angiotensinogen polymorphisms are also strongly
implicated as a risk factor for hypertension. The evolving
data on hypertension demonstrate that there are likely
to be individuals in the population who essentially have
a single-gene disorder—along with many others, pre-
sumably the majority, who have a complex trait with
multiple loci contributing to their increased susceptibil-
ity—and a continuum where any number of loci may
contribute to varying degrees for any one individual. It
is attractive to consider the possibility that there are still
a few major common alleles to be identified in hyper-
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tension and that the condition involves more locus het-
erogeneity—with major-gene effects in more patients
and families—than we anticipate. Perhaps this is not
beyond hope, given major ethnic differences in risk.
In attempting to derive some additional perspective
regarding complex traits, I found it useful to refer to the
report of a meeting, entitled “The Genetic Architecture
of Complex Traits,” that I had the opportunity to attend
at the end of 1997. The executive summary begins with
the following: “Most genetic traits of interest in popu-
lations of humans and other organisms are determined
by many factors, including genetic and environmental
components, which interact in often unpredictable ways.
For such complex traits, the whole is not only greater
than the sum of its parts, it may be different from the
sum of its parts. Thus complex traits have a genetic
architecture that consists of the genetic and environ-
mental factors that contribute to the trait, as well as
their magnitude and their interactions.”
As I listened to researcher after researcher emphasize
the enormous complexity of the problem, I think that
one of the “communications” from the meeting summed
it up the best for me, as follows: “The analysis of com-
plex traits does not lend itself to quick and easy solu-
tions”—and perhaps I might add “and thus applications
to the practice of medicine may be slow to evolve.”
In a more optimistic perspective, one more-recent pro-
posal is to move aggressively to identify thousands of
SNPs and to focus on the use of association studies to
identify common variants affecting disease risks (Lander
1996; Risch and Merikangas 1996; Collins et al. 1997).
SNPs may themselves be risk factors or might identify
nearby disease polymorphisms by virtue of linkage dis-
equilibrium. An emphasis on coding regions or cSNPs
that involve amino acid polymorphisms is envisioned.
The data for many such polymorphisms are probably
already embedded in private and public databases of
redundant cDNA sequencing, waiting to be unearthed.
This approach now has a substantial momentum and is
likely to identify numerous polymorphisms of disease
relevance. If many of the variants identified have very
modest phenotypic effects, they may be more useful for
dissecting pathogenesis and developing general thera-
peutic approaches than for genotype-based diagnosis
and intervention.
Along these lines, exciting data are being generated,
and I would particularly note the recent report of the
sequencing of 9.7 kb of the lipoprotein lipase gene (Clark
et al. 1998; Nickerson et al. 1998). Sequencing of this
region from 71 individuals, or 142 chromosomes, iden-
tified 88 variable sites, or 1/500 bp. This included 79
SNPs, of which 4 changed amino acids in the coding
sequence. Nine insertion/deletion variants were identi-
fied. On the one hand, this is exactly the type of data
we seek, but, on the other hand, the interpretation of
this extraordinary complexity is extremely challenging.
For today’s perspective, perhaps the most relevant fact
is that one of the amino acid polymorphisms was already
implicated as a risk factor in coronary atherosclerosis.
Given some of these possibilities regarding complex
traits, I will offer a few speculations. First, it is likely to
be proportionally more difficult to unravel genotype-
phenotype correlations with increasing numbers of loci
contributing to the phenotype in a single patient, and
genotype-based medicine may be slow to evolve for the
disorders with more-complex genetic etiology. On the
other hand, it seems likely that a modest or even sub-
stantial number of additional common disease–related
polymorphisms involving amino acid substitutions
(“coding SNPs” in today’s jargon) comparable to factor
V Leiden and apo E will be identified in the population
over the coming decade or two. Variants of this type
would seem to hold the greatest promise for the short
term. It would be favorable in terms of the potential for
research progress and therapeutic intervention if many
of the common disorders in the adult population in-
volved a single locus contributing a major portion of the
genetic risk in a single patient or family, even if different
loci were pivotal in different patients. The greater the
role of a major gene in an individual patient, the better
the prospects for genotypic diagnosis, understanding the
pathogenesis, and rational intervention. To the extent
that individual patients are affected by complex traits in
which many loci contribute to the susceptibility to dis-
ease, efforts to develop therapeutic intervention might
best be focused on some final common component of
pathogenesis, and efficacy may be similar for a broad
range of genotypes.
Given the relative importance of heart disease and
cancer in the adult population, I would like to briefly
consider these two conditions in the context of genomic
medicine. Focusing more specifically on coronary ath-
erosclerosis, we now know of innumerable loci that can
affect risks, including the LDL receptor; apolipoproteins
A–I, B, E, and others; lipoprotein(a); lipoprotein lipase;
loci affecting homocysteine levels; and others. There are
almost certainly numerous additional important loci
whose contribution to risk is yet to be defined. Consid-
ering these data, we might think that a genotyping panel
would be extremely valuable in complementing LDL and
HDL cholesterol values for the assessment of athero-
sclerotic risk. However, nongenetic factors are also very
important, and extensive genotyping is certainly not
widely utilized and may be difficult to justify. We know
that a modest proportion of patients have their risk de-
termined primarily by a single locus, as in the case of
familial hypercholesterolemia, but it seems likely that
genetic risk is determined by multiple loci for the ma-
jority of individuals with coronary atherosclerosis. For
families with a single major locus, aggressive efforts to
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establish the diagnosis at a gene-specific and mutation
level and to offer testing to extended families is a po-
tentially important strategy, particularly if there is evi-
dence for genotype-specific intervention. On the other
hand, we must consider the possibility that genotype-
based medicine will not be the way of the future, re-
garding coronary atherosclerosis. Brown and Goldstein,
in an editorial entitled “Heart Attacks: Gone with the
Century?” (1996), suggest that noninvasive screening
methods to detect coronary atherosclerosis in its earliest
stages, combined with aggressive use of the statin class
of HMG-CoA reductase inhibitors, might dramatically
reduce the incidence of myocardial infarction in the next
century. In preparing for today’s presentation, I con-
ferred with Dr. Goldstein, and he continues to envision
this scenario, with uncertain emphasis on genotype-spe-
cific intervention. It is difficult to predict the extent to
which diagnosis and management of coronary athero-
sclerosis risks will involve genotype-based or genotype-
independent medicine, but some combination of the two
is likely to prevail. A genetic-based further dissection of
the pathogenesis of and risk factors for atherosclerosis,
particularly the endothelial and inflammatory compo-
nents that are currently poorly defined, is sure to be
important. Although we, as geneticists, would find it
intellectually far more satisfying to evolve toward a ge-
notype-based prevention, the widespread use of statins
or other novel interventions based on coronary imaging,
rather than genotyping, may prove to be the most prag-
matic course.
Turning to genomic medicine and cancer, I would like
to narrow the discussion to colon cancer, to highlight a
few perspectives. You are aware of the remarkable mo-
lecular data demonstrating mutations in the APC locus
causing polyposis of the colon and mutations in mis-
match-repair genes causing HNPCC, as exemplified by
the work of Bert Vogelstein, this year’s Allan Award
recipient. I asked Dr. Vogelstein what he perceived to be
the current and future impact of genotype-based medi-
cine in the field of colon cancer. He felt that “the impact
was already dramatic in the case of familial polyposis
and HNPCC,” with numerous lives undoubtedly saved
by family evaluations and appropriate screening for pa-
thology (B. Vogelstein, personal communication). There
are exciting new data suggesting that chemoprevention
for colon cancer may be a significant strategy to delay
or preclude the need for colectomy.
Turning for a moment to polyposis of the colon, we
learn an interesting lesson regarding the milder pheno-
typic spectrum associated with allelic heterogeneity. We
start with the evidence that classical polyposis families
represent only a small proportion of all cases of colon
cancer. This is followed by reports of families with at-
tenuated disease with smaller numbers of polyps but still
increased risk of colon cancer. These kinds of observa-
tions might lead us to suspect that the genetic contri-
bution to many cancers and to adult diseases in general
may yet prove greater than is generally appreciated. The
occurrence of the I1307K allele at the APC locus is par-
ticularly fascinating and instructive (Laken et al. 1997).
In this instance, a single nucleotide mutation generates
an eight-base tract of adenine nucleotides in the coding
region. This allele, then, is hypermutable, with increased
occurrence of frameshift mutations. The mutation is
found in 6%–8% of individuals of Ashkenazic descent.
The allele is associated with an increased risk of colo-
rectal cancer and perhaps other tumors, but the pene-
trance is quite low, with only a 1.5–2.0 odds ratio for
various tumors. Although this allele is conceptually fas-
cinating, the low penetrance makes its clinical impor-
tance uncertain, and it would seem to be a questionable
candidate for population-based screening, depending
once again on the potential for intervention.
In the case of HNPCC, there is an immediate oppor-
tunity for improving the practice of family-based ge-
nomic medicine. The incidence of HNPCC is ∼1/
200–1,000, in various studies, and related genotypes are
estimated to cause ∼3% of colorectal cancer (Kinzler
and Vogelstein 1998). In the case of HNPCC, there is a
very high penetrance, with one study reporting a lifetime
risk for colorectal cancer of 74% in males and 30% in
females, an impressive sex difference (Dunlop et al.
1997). The risk of uterine endometrial cancer is very
high, at 42%. Heterozygous, germ-line, and loss-of-
function mutations at any of four loci involved in mis-
match repair (MSH2, MLH1, PMS2, and PMS1) can
cause HNPCC. There is strong evidence that screening
for polyps and the option of colectomy provide very
meaningful intervention. The lifetime penetrance for var-
ious cancers is a 91% total risk for males and 69% for
females (Dunlop et al. 1997). Interestingly, these data
were generated in Scotland by studying 156 relatives of
only six probands, to identify 67 gene carriers; this is
11 gene carriers found for each proband. In families with
a history of colon cancer or in individuals presenting
with newly diagnosed colon cancer, it would be ex-
tremely desirable to identify those individuals with germ-
line mutations involving the mismatch-repair genes. The
vast majority of individuals with HNPCC have inherited
rather than de novo mutations, as is also true for many
other forms of genetic cancer predisposition, including
BRCA1 and BRCA2. This means that diagnosis of a
single index case can often lead to the identification of
innumerable at-risk relatives for whom careful family
evaluations could prevent many cancer deaths. Once
again, the availability and quality of intervention are
major determinants of the attractiveness of such family-
based screening. In general, intervention for the cancer
genetic syndromes varies from extremely valuable but
certainly not simple, for HNPCC, to complex for
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BRCA1 and BRCA2, to very problematic for Li-Frau-
meni syndrome. At present, the majority of individuals
with HNPCC-related cancers probably are not having
their germ-line mutation recognized, and much more
effective programs in this regard could save many lives.
If HNPCC represents 3% of colorectal cancer and there
are ∼60,000 deaths from this condition in the United
States each year, ∼1,800 lives could be saved per year if
we could eliminate deaths from colorectal cancer in
HNPCC families. Perhaps the biggest challenge is to ed-
ucate family members about the great benefits of screen-
ing and to convince them that the benefits outweigh the
burdens of testing.
The use of family-based rather than population-based
screening for identification of at-risk genotypes is rele-
vant to many autosomal dominant disorders, when most
cases represent inherited rather than de novo mutations.
Any family-based strategies depend on the level of in-
terest within at-risk families, which in turn depends on
our ability to develop definitive interventions that are
so clearly beneficial that they overcome the understand-
able skepticism and fears regarding testing.
This leads me to the possibility that reproductive op-
tions may deserve greater consideration for these dom-
inant disorders. Many disorders—such as HNPCC,
BRCA1/BRCA2, MODY, triplet-repeat neurodegen-
erative disorders, and familial hypercholesterole-
mia—could be considered in this context. In many cases,
the potential for therapeutic advances for these disorders
is intriguing but uncertain. With regard to the many
disorders where the majority of cases represent inherited
mutations, it seems safe to assume that couples would
prefer to bear children spared of these mutations, par-
ticularly if therapeutic advances are slow to evolve. The
incidence of many of these disorders theoretically could
be dramatically reduced in the population, through re-
productive avoidance. Although most couples would
welcome a simple method to preferentially conceive chil-
dren free of the disease genotype, few are ready to con-
sider conventional prenatal diagnosis and selective ter-
mination of pregnancy, in this clinical setting. Perhaps
preimplantation diagnosis could play a much greater
role. In view of the fact that the risk of disease would
be eliminated for future generations within a family, the
burden, inefficiencies, and cost of preimplantation di-
agnosis might be acceptable, to avoid the risk of serious
and poorly treatable disorders for generations. Thus,
another challenge for young investigators is to greatly
enhance current methods for preimplantation diagnosis.
One substantial obstacle in avoiding these dominant dis-
orders through reproductive options is the need for
young, reproductive-aged family members at risk to put
aside their fears and learn about the disorder within a
family. In a more futuristic vein, it is interesting to spec-
ulate whether disorders of this type might be avoided
through some completely novel strategy such as sorting
of sperm on the basis of single-nucleotide differences.
This would permit reducing the incidence of a disorder
by half, in each generation. Perhaps this fantasy is be-
yond the reach of even the brightest young investigators
in our midst. In the reproductive strategies for this group
of disorders, there are many important issues. These in-
clude age-related penetrance, with many years of good
health leading us to think less about reproductive pre-
vention; the uncertainties of present and future thera-
peutic interventions; and, perhaps most important, the
need for reproductive-aged family members to become
intimately involved in assessing their genetic risks. If a
disorder is more serious and resistant to alternative ther-
apies, the impetus to consider reproductive avoidance is
greater, so that such an option may be much more rel-
evant to a disorder such as Li-Fraumeni syndrome,
where treatment is very difficult, than for familial hy-
percholesterolemia, where drug therapy is of great ben-
efit. I would again propose the challenge to develop
novel technologies to allow families in this circumstance
to preferentially bear children free of serious deleterious
mutations.
As I move toward the end of my presentation, I would
like to return to my opening questions: How will genetic
advances impact the practice of medicine over the next
decade or two? One way genetics will impact the practice
of medicine is through new advances in our discipline.
I think it is quite predictable that there will be major
technical improvements in detecting cytogenetic abnor-
malities, and I would propose that some of these im-
provements may be of the magnitude that we observed
with the development of banded karyotypes. Many of
our patients with mental retardation and birth defects
may have cytogenetic abnormalities detectable by new
technologies. I think we can also predict with confidence
that there will continue to be major advances in the
identification of disease genes and mutations, with major
benefits for diagnosis and counseling. It would seem that
we are completing the first of what may be 2 or 3 decades
of a research boom in this arena. Although we have
identified disease genes for the vast majority of more-
common, single-gene disorders, similar developments for
rarer disorders should occur at a faster and faster pace.
We should also expect the discovery of many more dis-
ease-related coding SNPs. I anticipate incremental ad-
vances in disease-specific therapies, such as the example
of glucocorticoid-remediable aldosteronism, which I
mentioned, or implantable pacemakers for genetic dis-
orders causing arrhythmias and sudden death. In the
next few years, I anticipate the identification of single-
gene or major-gene effects contributing to psychiatric
illness, perhaps starting with schizophrenia or manic de-
pression. I speculate that we will see remarkable phar-
macological advances, with drugs for Alzheimer disease
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and drugs for neurodegenerative triplet-repeat disorders,
and improvements in drugs for atherosclerosis. I antic-
ipate that genetic dissection of pathogenesis will be a
major factor in developing these novel therapies. I an-
ticipate the development of drugs that have true effect-
iveness for weight control, on the basis of genetic insight
into the pathogenesis of obesity. These drugs would have
major relevance to diseases such as hypertension and
type II diabetes. The use of chemoprevention to reduce
cancer risks is also a very promising and relatively new
area for further study, although it seems unlikely that
such strategies would completely eliminate the risk of
some of the more penetrant genetic predispositions to
cancer. Of course, there will be the unanticipated break-
throughs, and we might ask ourselves what the next
equivalent of PCR in human genetics will be. Will we
see breakthroughs that have a dramatic and generaliz-
able relevance to therapeutic intervention as opposed to
diagnosis?
There is also the question of whether somatic gene
therapy might eventually live up to its promise. On this
issue I will enroll as a somewhat chastened, but per-
sistent, optimist. Continuing efforts provide some evi-
dence for improvements in nonviral delivery systems,
adeno-associated viral vectors, newer generations of
adenoviral vectors, and lentiviral vectors. The ability to
produce extracellular proteins such as clotting factors,
erythropoietin, and other hormones seems imminent,
through delivery to skeletal muscle, hepatocytes, or other
sites. The potential for persistent expression in hepato-
cytes could provide correction of numerous inborn er-
rors of metabolism and treatment of other disorders. The
potential to correct genetic defects in bone-marrow stem
cells, by one or another strategy, continues to hold great
promise for the treatment of globally important disor-
ders such as sickle-cell anemia and b-thalassemia. I be-
lieve that we should continue to press for advances in
somatic gene therapy, in the hope that the benefits we
might have envisioned for the current decade will come
to fruition in the next decade or two.
Another way for genetics to impact the practice of
medicine is for us to draw certain lessons from available
data. As we consider the potential for genomic medicine,
it is obvious that genes of major effect and genotypes
causing serious burden or high penetrance, such as
HNPCC, are of much greater potential importance than
alleles with smaller effects, such as for the I1307K mu-
tation at the polyposis locus. Within “complex traits,”
circumstances where a single locus has a major effect
appear much more tractable for applications of genomic
medicine than when multiple loci determine suscepti-
bility in a single individual. The availability of interven-
tion is the most crucial variable. We are paralyzed by
its absence in the case of apo E genotypes and Alzheimer
disease, but we have more to offer in the case of phle-
botomy and hemochromatosis. Some therapies will be
very genotype specific, such as phenylacetate for sickle-
cell anemia or enzyme replacement for Gaucher disease,
while others may be broadly applicable in the popula-
tion, benefiting people of widely different genotypes, as
may be the case for folic acid supplementation, anti-
oxidants, or statin drugs. The more widely applicable
interventions raise the rather frightening specter of large
portions of the population taking numerous medications
on a lifelong basis, something we would need to consider
carefully, case by case. In some instances it may be quite
appropriate to consider population-based testing, as per-
haps in the case of a1-antitrypsin, hemochromatosis, or
pharmacogenetic traits, while family-based testing may
be more appropriate in disorders such as HNPCC. We
should keep in mind that genotypic information col-
lected in one generation may dramatically alter consid-
erations for future generations. Increasingly, children
will be born into families in which they grow up to learn
that their parents have particular genotypes of disease
relevance. This may be acceptable if we have restricted
ourselves to collecting genotypic information that allows
meaningful therapeutic intervention. In some cases, we
may encounter milder alleles at loci initially discovered
on the basis of severe phenotypes, as I mentioned for
polyposis and speculated on in the context of sodium-
channel genes and hypertension. Attempts to educate
medical providers and the public are likely to be suc-
cessful at the time when new programs are implemented,
as has been experienced to date with new genetic
services.
Let us now return to my other question: What should
we be doing to influence these developments? I have
suggested that we should explore expanded reproductive
screening and prenatal diagnosis for the group of dis-
orders I characterize as seemingly insurmountable, fo-
cusing on couples seeking maximal prenatal screening.
I think that we should work to make population-based
screening for treatable adult diseases a reality, and I have
emphasized how we could be saving lives taken by he-
mochromatosis. I have advocated identifying probands
and using family-based screening for treatable dominant
disorders, as exemplified by how we could be saving
lives taken by HNPCC.
In conclusion, I want to lay out some challenges or
recommendations for us as a Society. We cannot be
oblivious to the risks of genetic testing or to the fears it
engenders. I have focused excessively on opportunities
and have given insufficient time to the risks, harms, and
burdens of these approaches, and we do need to rec-
ognize these risks, but we should not let these concerns
prevent us from vigorously exploring the benefits of ge-
netic testing. Some inconveniences, emotional burdens,
and financial costs can be accepted if the benefits are
real and substantial, as we have experienced for newborn
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screening. Both the scientific and the lay press are em-
phasizing the risks, as exemplified by a recent headline
citing the advice of a British committee properly cau-
tioning against the risks of genetic testing for mental
disorders (Dickson 1998). We need comparable empha-
sis on the potential benefits. To make the benefits of
genomic medicine clearly outweigh the risks, we must
develop more and better therapeutic interventions. Al-
though a research society such as ours is dedicated, in
part, to the pursuit of knowledge for its own sake, and
although we can take great pride in the molecular def-
inition of genetic disease that is being developed, I be-
lieve we should make every effort to maximize the ben-
efits to society, largely through improved disease
prevention and therapeutic intervention. We must de-
velop new technologies and approaches to solve difficult
problems. We should encourage young investigators to
take on the most difficult challenges, some of which I
have mentioned. Are we ready to use the insights of
chemical individuality, as recognized by Garrod (1931),
to practice a new form of genotype-based medicine? The
membership of our Society encompasses broad expertise
in human genetics, and it is our responsibility to provide
the leadership to maximize the benefits of human genetic
knowledge for society.
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